Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models by Thotala, Dinesh et al.




Cytosolic phospholipaseA2 inhibition with
PLA-695 radiosensitizes tumors in lung cancer
animal models
Dinesh Thotala
Washington University School of Medicine in St. Louis
Jeffrey M. Craft
Washington University School of Medicine in St. Louis
Daniel J. Ferraro
Washington University School of Medicine in St. Louis
Rama P. Kotipatruni
Washington University School of Medicine in St. Louis
Sandeep R. Bhave
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Thotala, Dinesh; Craft, Jeffrey M.; Ferraro, Daniel J.; Kotipatruni, Rama P.; Bhave, Sandeep R.; Jaboin, Jerry J.; and Hallahan, Dennis




Dinesh Thotala, Jeffrey M. Craft, Daniel J. Ferraro, Rama P. Kotipatruni, Sandeep R. Bhave, Jerry J. Jaboin, and
Dennis E. Hallahan
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/1605
Cytosolic PhospholipaseA2 Inhibition with PLA-695
Radiosensitizes Tumors in Lung Cancer Animal Models
Dinesh Thotala1,2., Jeffrey M. Craft1., Daniel J. Ferraro1, Rama P Kotipatruni1, Sandeep R. Bhave5,
Jerry J. Jaboin1,2, Dennis E. Hallahan1,2,3,4*
1Department of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri, United States of America, 2 Siteman Cancer Center, Washington University in
St. Louis, St. Louis, Missouri, United States of America, 3Hope Center, Washington University in St. Louis, St. Louis, Missouri, United States of America, 4Mallinckrodt
Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri, United States of America, 5 School of Medicine, Washington University in St. Louis, St. Louis,
Missouri, United States of America
Abstract
Lung cancer remains the leading cause of cancer deaths in the United States and the rest of the world. The advent of
molecularly directed therapies holds promise for improvement in therapeutic efficacy. Cytosolic phospholipase A2 (cPLA2) is
associated with tumor progression and radioresistance in mouse tumor models. Utilizing the cPLA2 specific inhibitor PLA-
695, we determined if cPLA2 inhibition radiosensitizes non small cell lung cancer (NSCLC) cells and tumors. Treatment with
PLA-695 attenuated radiation induced increases of phospho-ERK and phospho-Akt in endothelial cells. NSCLC cells (LLC and
A549) co-cultured with endothelial cells (bEND3 and HUVEC) and pre-treated with PLA-695 showed radiosensitization. PLA-
695 in combination with irradiation (IR) significantly reduced migration and proliferation in endothelial cells (HUVEC &
bEND3) and induced cell death and attenuated invasion by tumor cells (LLC &A549). In a heterotopic tumor model, the
combination of PLA-695 and radiation delayed growth in both LLC and A549 tumors. LLC and A549 tumors treated with a
combination of PLA-695 and radiation displayed reduced tumor vasculature. In a dorsal skin fold model of LLC tumors,
inhibition of cPLA2 in combination with radiation led to enhanced destruction of tumor blood vessels. The anti-angiogenic
effects of PLA-695 and its enhancement of the efficacy of radiotherapy in mouse models of NSCLC suggest that clinical trials
for its capacity to improve radiotherapy outcomes are warranted.
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Introduction
Lung cancer is a leading cause of cancer death in United States.
The American Cancer Society’s estimates in 2012 indicate that
there were over 225,000 new cases and over 160,000 deaths from
lung cancer in United States [1]. Radiation therapy (RT) remains
an integral part of lung cancer management [2]. In the past
decade, there have been substantial improvements in radiation
treatment outcomes attributable to advances in clinical, physics,
and biology research [3]. Despite these improvements in
therapeutic regimens, local recurrence of lung cancer remains a
persistent problem [4]. Most patients with unresectable non–small
cell lung cancer (NSCLC) have a poor prognosis with median
survivals of approximately 18 months, despite aggressive therapy
[5,6]. Thus, there is an urgent need to develop more effective
approaches for the treatment of NSCLC.
Ionizing radiation (IR) not only damages nuclear DNA, but also
activates a series of signaling cascades within the cell [7,8].
Phospholipase A2 (PLA2, catalyzes the hydrolysis of membrane
phospholipids at the SN-2 position to release lipid second
messengers [9]. Ionizing radiation activates cytosolic phospholi-
pase A2 (cPLA2) in endothelial cells [10]. After activation, cPLA2
cleaves palmitic acid to form phosphatidylcholine (PC)
[11,12,13,14] which then leads to production of lysophosphati-
dylcholine (LPC), lysophosphatidic acid (LPA), prostaglandin E2
(PGE2) and arachidonic acid [15,16,17,18]. Arachidonic acid and
LPA play important role in invasion and signaling during cancer
progression [14,19,20,21]. The activation of cPLA2 stimulates
proliferation of endothelial cells and promotes the formation of
vascular networks [16,17]. LPC triggers the downstream activa-
tion of phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-
activated protein kinase(MAP)/extracellular signal regulated
kinase (ERK), which. results in increased cell viability of the
endothelium in the tumor microenvironment [16,17,22]. Activa-
tion of cPLA2 in the tumor microenvironment leads to increased
vasculature and enhanced tumorogenesis leading to radioresis-
tance of the tumor and diminishing the efficacy of the
radiotherapy [23,24]. Combination of irradiation with inhibition
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of cPLA2 in preclinical lung cancer tumor models has been shown
to suppressed tumor growth and reduced angiogenesis [25,26].
Previous investigations have used cPLA2 inhibitors unsuited for
translation to the clinic due to their toxicity [17]. We studied the
effects of PLA-695, a cPLA2 inhibitor that has already been tested
in clinical trials. The phase I study (NCT00366262) evaluating the
safety of PLA-695 compared to placebo and naproxen has been
completed (clinical trials.gov). Later, the Phase II clinical trial
(NCT00396955) compared 4 dose regimens of PLA-695, naprox-
en, and placebo in subjects with osteoarthritis of the knee (clinical
trials.gov). The present study determined the efficacy of PLA-695
in combination with irradiation to treat mouse models of lung
cancer.
We found that PLA-695 inhibits radiation induced phosphor-
ylation of ERK and Akt in cultured endothelial cells. PLA-695 in
combination with irradiation prevented endothelial cell migration.
PLA-695 enhanced radiation induced cell death and attenuated
invasion of lung cancer cells. PLA-695 inhibited the formation of
new blood vessels and angiogenesis [26]. In addition, PLA-695
enhanced the efficacy of radiation in two mouse models of lung
cancer.
Methods
Cell Culture and Treatment
Primary culture of Human Umbilical Vein Endothelial Cells
(HUVECs) pooled from multiple donors was obtained from
Cambrex (East Rutherford, NJ, USA) and maintained in complete
EBM-2 medium (Cambrex). Cells from passages 2–5 were used in
this study. HUVECs were starved for 1 hour before treatment in
additive-free EBM-2 medium. 3B11 microvascular cells were
obtained from American Type Culture Collection (Manassas, VA)
and maintained in DMEM with 5% fetal bovine serum (FBS).
Cells from passages 3–6 were used in this study. 3B11s were
starved in DMEM +1% FBS for 3 hours prior to all studies. PLA-
695 was obtained from Pfizer Inc under the Pfizer-WU biomedical
agreement. For the irradiation of cells, Therapax 250 X-ray
machine (Pantak Inc., East Haven, CT, USA) delivering 2.04 Gy/
min at 250 kVp was used. Due to high sensitivity of HUVECs to
temperature and pH, cells were maintained in an incubator
adjacent to the irradiator prior to and after treatment. In
experiments with PLA-695, cells were treated for 45 minutes
prior to IR (3 Gy) with either dimethylsulfoxide (DMSO, vehicle
control) or varying concentration of drug in DMSO (10–600 nM).
Co-culture Clonogenic Survival Assay
HUVEC (1.06106) and bEnd.3 cells (1.06106) were plated in
100 mm plates and after 24 h, A549 (26106) and LLC (26106)
cells were plated onto transwell inserts (Corning Inc., Corning,
NY). After co-culture for 24 h, cells were treated with 300 nM of
PLA-695 or vehicle control DMSO for 45 minutes prior to IR
with 0, 2, 4, 6 or 8 Gy. After the treatments as co-culture with
either PLA-695 or DMSO calculated numbers of LLC and A549
cells were plated to enable normalization for plating efficiencies.
Clonogenic assays were also performed with LLC and AF549
alone. Fixed numbers of cells were plated to enable normalization
for plating efficiencies. Cells were allowed to attach for 5 hours
and then treated with 300 nM of PLA-695 or vehicle control
DMSO for 45 minutes prior to IR with 0, 2, 4, 6 or 8 Gy. After 7–
10-day incubation plates were fixed with 70% EtOH and stained
with 1% methylene blue. Colonies consisting of .50 cells were
counted by viewing the plates under a microscope. The survival
fractions were calculated as (number of colonies/number of cells
plated)/(number of colonies for corresponding control/number of
cells plated).
Colorimetric Cell Proliferation Assay
Cell proliferation was determined using cell titer 96 Aqueous
Non-Radioactive Cell Proliferation Assay reagent (Promega). The
assay was performed following the manufacturers protocol. Briefly
cells were treated with either DMSO control or 300 nM PLA-695
for 45 minutes and irradiated with 3 Gy. The medium was
changed after 1 hour and the plates were incubated for 96 h. Cell
viability was measured colorimetrically after 96 h by measuring
absorbance at 490 nm. Experiments were performed in triplicate
and standard errors were calculated.
Morphologic Analysis of Cells Stained with DAPI
LLC and A549 cells were grown in chamber slides and treated
with either DMSO or 300 nM PLA-695 for 45 minutes and then
irradiated with 3 Gy. At 96 h post-irradiation, cells were fixed in 4
paraformaldehyde and then stained with 2.5 mgml 49,6-diamidino-
2-phenylindole (DAPI) in phosphate-buffered saline. Photomicro-
graphs were taken using an Olympus BX60 fluorescent micro-
scope equipped with digital camera. Multinucleated cells and cells
containing giant nuclei were counted in several randomly selected
fields. The average percentage of such cells over total cell number
was calculated from three experiments.
Tumor Transwell Invasion Assay
The tumor Transwell Matrigel Invasion Assay was used to
monitor tumor-endothelium interactions and cell migration. This
assay employs a simplified Boyden chamber-like design that
consists of two chambers separated by a filter coated with
Matrigel. A549 (1.06106 cells/well) or LLC (0.66106 cells/well)
were suspended in serum-free media and added to the top of 24
well plates with 8 mm basement membrane matrix-coated
polycarbonate membrane inserts (Bedford, MA, USA). 500 uL
of fresh medium was added to the bottom chamber as chemo-
attractant. For radiosensitization studies, both chambers were then
treated with vehicle DMSO or 300 nM PLA-695 for 45 minutes
prior to IR with 4 Gy. Cells migrated from the top chamber
through the coated filter pores to the bottom of the filter. After 24
hours, remaining cells in the upper chamber of the membrane
inserts were removed using a wet cotton swab. The cells that
adhered on the outer surface of the transwell insert membrane
which had invaded through the Matrigel were fixed with 100%
methanol and stained. Cells that had invaded in 7–10 high power
field (HPF) from each sample were counted using Image J
Software (NIH, Bethesda, MD), and the average number of cells
that invaded through the membrane per HPF was calculated.
Mean and standard error for each treatment group were
calculated for each group.
Signal Transduction Pathway Analysis
After treatment, HUVECs cells were harvested at the indicated
times. Total protein extraction was performed using M-PER
reagent (Pierce, Rockford, IL, USA) containing protease inhibitors
and phosphatase inhibitors II and III (Sigma, MO). Protein
concentration was quantified using BCA Reagent (Pierce). Protein
extracts (40 mg) were subjected to western immunoblot analysis
using antibodies for the detection of phospho-Akt (Thr308/
Ser473), phospho-ERK1/2, (Thr202/Tyr204), total Akt, and total
ERK1/2 (all from Cell Signaling Technologies.
Danvers, MA, USA). Antibody to actin (Sigma-Aldrich, St.
Louis, MO) was used to evaluate protein loading in each lane.
Cytosolic PhospholipaseA2 Inhibition with PLA-695
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Immunoblots were developed using the Western Lightning
Chemiluminescence Plus detection system (PerkinElmer, Well-
esley, MA, USA) according to the manufacturer’s protocol.
Cell Migration
HUVEC and bEND3 cells were grown to 70%–80%
confluency in 60 mm plates. Three parallel wounds were
created on each plate by scratching the cell monolayer with a
200-mL pipette tip, and boundaries of the wounds were marked.
Cells were treated for 1 hour with vehicle (DMSO) or 300 nM
PLA-695, followed by 3 Gy IR. After 24 hours, the cells were
photographed, and cells found inside and outside of the wound
boundaries were counted from six HPFs per sample. Cells that
spanned the boundaries were classified as non-migrated cells.
Cell density within the wound is presented as a percentage of
total cell density in the plate. Results are from triplicate samples
in three independent scratch assays.
Tumor Growth Delay
The Institutional Animal Care and Use Committee of
Washington University in St. Louis specifically approved this
study. LLC (106) or A549 (106) cells were implanted into the right
footpad C57/BL6 mice. Once all tumors became measurable by
plethysomography, as determined by volume of tumor-bearing
footpad minus volume of contralateral footpad, the mice were
serpentine sorted into groups of six to seven animals representing
similar distributions of tumor sizes (range= 40–70 mm3). Tumor–
bearing mice were injected intraperitoneally with vehicle (DMSO)
or PLA-695 at 7.5 mg per kg body weight once daily for five
consecutive days. Thirty minutes after drug injection mice were
anesthetized with isoflurane and positioned in the Pantak
irradiator and irradiated with 2 Gy daily for five consecutive days
for a total of 10 Gy. Lead blocks (10 mm thick) were used to shield
the head, thorax, and abdomen. Tumor size was monitored
longitudinally with plethysmography. Mice were sacrificed by
CO2 asphyxiation once tumors reached a volume of approxi-
mately 700 mm3 or when ulceration became apparent on the
footpad per Animal Care guidelines.
In vivo Angiogenesis Assay Dorsal Skin-fold Chamber
Model
The implantation technique of the dorsal skin-fold chamber
model has been described previously [27]. Briefly, diffusion
chambers containing LLC cells (16106 cells per chamber) were
inserted in the dorsal air sac made by making a superficial incision
horizontally along the edge of the dorsal air sac. The skin was
carefully sutured after placing the chambers underneath the mice
skin. The mice treatments were performed 5 to 7 days following
surgical insertion of the diffusion chambers. The skin fold covering
the chambers was carefully removed after euthanizing the mice
and photographed under visible light. The number of tumor
induced blood vessels was counted in ten different fields within the
chamber in the area of the air sac fascia.
Histological Analysis of Tumor Vasculature
The tumor bearing mice were sacrificed 24 hours after the final
treatment and the tumors were resected, fixed in formalin,
embedded in paraffin and sectioned. Sections (5 mm thick) were
treated with 20 mg/ml proteinase K for 30 minutes at room
temperature and then were incubated overnight with a rabbit
polyclonal antibody against human Von Willebrand factor (vWF)
(1:100 dilution; Dako, Carpinteria, CA). Tissue sections were
subsequently incubated with Alexa Fluor 488–conjugated goat
anti-rabbit IgG (1:500 dilution; Invitrogen Molecular Probes) for 1
hour at room temperature. Alexa Fluor 488–stained vessels were
counted in three randomly selected HPFs on each of three sections
per tumor. Vascularity was determined as the average number of
stained vessels per HPF. Tumor vascular cross sectional area was
determined similarly, using NIH Image J software, in which the
area enclosed by vessels was divided by total area of the HPF to
determine percent vascular area.
Statistical Analysis
The mean and standard error of the mean (SEM) of each
treatment group were calculated for all experiments. The number
of samples is indicated in the description of each experiment.
Students T-test was use to compare two treatment groups. Analysis
of variance (ANOVA) was used to compare treatment effectiveness
in tumor growth delay studies. A p-value of ,0.05 was considered
statistically significant.
Results
Effect of PLA-695 on Pro-survival Signaling after
Radiation
Activation of ERK and Akt occurs rapidly following radiation in
HUVEC cells (Fig. 1). Treatment with PLA-695 attenuates the IR
induced ERK phosphorylation in a dose-dependent manner (Fig. 1
A). ERK activation is reduced to baseline (sham-treated cells) by
300 nM of PLA-695. At higher concentrations, (600 nM), the
levels of ERK phosphorylation fall below baseline levels. The IR
induced Akt phosphorylation was also abrogated when HUVEC
cells were treated with 300 nM of PLA-695(Fig. 1 B). We found
similar results in 3B11 cells treated with 300 nM PLA-695(Fig. 1 C
and D).
PLA-695 Sensitizes A549 and LLC Cells to Ionizing
Radiation
To evaluate the role of cPLA2 in the viability of irradiated
lung cancer cells, we treated mouse lung cancer cell line LLC
and human lung cancer cell line A549 with 300 nM of PLA-
695 for 45 minutes prior to irradiation. We performed
clonogenic assays either as independent cultures (Fig. 2A) or
in co-culture (Fig. 2B) with endothelial cells (LLC with bEND3
and A549 with HUVEC). The plating efficiency of LLC cells
was 66% for DMSO treated cells and 60% for PLA-695 treated
cells. The plating efficiency of A549 cells was 64% for DMSO
treated cells and 52% for PLA-695 treated cells. The cells were
normalized for plating efficiency when calculating the survival
fraction for clonogenic assays. Pretreatment of lung cancer cell
lines with PLA-695 prior to IR had no impact on clonogencity
when grown as independent cultures of either in LLC (2 Gy
P= 0.53, 4 Gy P=0.87, 6 Gy P=0.02, 8 Gy P=0.01) or A549
(2 Gy P= 0.753, 4 Gy P= 0.441, 6 Gy P=0.636) (Fig. 2A).
LLC and A549 cells grown as co-cultures and treated with
PLA-695 prior to IR showed a significantly decreased cell
survival in both LLC cells (2 Gy P=0.003, 4 Gy P,0.001,
6 Gy P,0.001, 8 Gy P= 0.012) and A549 cells (2 Gy P=0.163,
4 Gy P,0.001, 6 Gy P,0.001, 8 Gy P= 0.031) as compared to
cells treated with radiation alone (Fig. 2B). Dose enhancement
factors were calculated at 10% cell survival by dividing the dose
of radiation from the radiation-only survival curve with the
corresponding dose from the PLA-695 plus radiation curve. The
dose enhancement factors were 1.17 for the LLC cells, 1.28 for
A549 cells (Fig. 2B).
Cytosolic PhospholipaseA2 Inhibition with PLA-695
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PLA-695 Reduces Proliferation in Endothelial and Lung
Cancer Cells after Irradiation
To elucidate the role of cPLA2 in both the endothelial cells
and lung cancer cells, we investigated how PLA-695 affects
proliferation in LLC, A549, bEND3 and HUVEC cells (Fig. 3A).
Equal numbers of LLC, A549, bEND3 and HUVEC cells were
plated in a 96 well plate. The following day, cells were treated
with 300 nM of PLA-695 for 45 minutes prior to IR. The
plates were read at 24, 48, 72, or 96 h using the colorimetric
cell proliferation assay by measuring the absorbance at 490 nm.
bEND3 cells treated with PLA-695 alone showed a significant
reduction in cell proliferation compared to DMSO at 24 h (P
,0.001), 48 h (P= 0.002) and 96 h (P ,0.001) and at 72 h
(P = 0.047). bEND3 cells treated with combination treatment of
PLA-695 with IR showed a significant reduction in cell
proliferation compared to IR alone at 72 h (P= 0.001) and
96 h (P= 0.002) and reduced proliferation at 24 h (P= 1.0) and
48 h (P= 0.023). HUVEC cells treated with PLA-695 alone
showed a significant reduction in cell proliferation compared to
DMSO at 24 h (P= 0.003), 48 h (P= 0.016), 72 h (P= 0.013),
and 96 h (P ,0.001). HUVEC cells treated with combination
treatment of PLA-695 with IR showed a significant reduction in
cell proliferation compared to IR alone at 24 h (P = 0.004) 72 h
(P= 0.002) and 96 h (P ,0.001). LLC cells treated with PLA-
695 alone showed reduction in cell proliferation compared to
DMSO at 24 h (P = 0.076), 48 h (P= 0.017), 72 h (P= 0.028)
and 96 h (P= 0.175). LLC cells treated with combination
treatment of PLA-695 with IR showed a significant reduction
in cell proliferation compared to IR alone at 24 h (P = 0.001),
48 h (P= 0.010), 72 h (P ,0.001) and 96 h (P ,0.001). A549
cells treated with PLA-695 alone showed a reduction in cell
proliferation compared to DMSO at 24 h (P= 0.017), 48 h
(P= 0.008), 72 h (P= 0.070) and 96 h (P= 0.079). A549 cells
treated with a combination treatment of PLA-695 with IR
Figure 1. Effect of PLA-695 on pro-survival signaling after radiation. HUVEC cells (A) were treated with various concentrations of PLA-695 as
indicated for 45 min before treatment with 3 Gy, cells were lysed at 5 min after IR. HUVEC (B) and 3B11 (C&D) cells were treated with 300 nM PLA-695
for 45 min before treatment with 3 Gy. Cells were lysed at 5 min after IR. Shown are immunoblot analyses using specific antibodies to phospho-
AktSer473, total Akt, phospho-ERK1/2, total ERK1/2, and actin.
doi:10.1371/journal.pone.0069688.g001
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showed significant reduction in cell proliferation compared to
IR alone at 72 h (P= 0.003) and 96 h (P= 0.003).
PLA-695 Enhances Cell Death in Irradiated Lung Cancer
Cells
cPLA2 has been shown to activate signaling through the Ras/
Raf/ERK pathway [10,28]. Activation of phospholipase A2 has
also been indicated to be the cause of delayed cell death induced
by H2O2 [29]. We studied cell death in LLC and A549 by staining
for Annexin V and,PI using flow cytometry at 24, 48, 72 and 96 h
after IR (Fig. 3B). PLA-695 treatment of LLC cells did not induce
any significant cell death at all of the tested time points. A549 cells
treated with PLA-695 showed a slight increase in cell death with
time. IR alone induced a level of cell death in both LLC and A549
cells that was similar at all the time points tested (24, 48, 72 and
96 h). Combined treatment with PLA-695 and IR did not induce
increased cell death compared to IR alone at 24 h in both LLC
cells (P = 0.831) and A549 cells (P = 0.192). At 48 hours the
combined treatment showed modest cell death in LLC cells
(P = 0.100) and significant cell death in A549 cells (P ,0.001). At
72 h and 96 h, the combined treatment showed significant cell
death in both LLC cells (P ,0.001) and A549 cells (P ,0.001).
We next evaluated the nuclear morphology of irradiated cells
using DAPI staining (Fig. 4); the results were similar to the
assessment done by Annexin V/propidium iodide staining. At
96 h post irradiation, the combined treatment with PLA-695 and
IR resulted in significantly more multinucleate cells and cells with
enlarged nuclei (characteristic of mitotic catastrophe) in both LLC
cells and A549 cells (P 0.006), when compared to IR alone (LLC,
P= 0.001; A549, P= 0.006) and PLA695 alone(LLC, P=0.001;
A549, P= 0.002).
Figure 2. PLA-695 enhances clonogenic cell death in LLC and A549. LLC and A549 cells were grown independently (A) or as co-cultures (B)
with bEND3 and HUVEC cells and were treated with DMSO or 300 nM PLA-695 in serum free media for 45 min prior to IR. The cells were then
irradiated with 0, 2, 4, 6 and 8 Gy and plated for clonogenic survival assay. After 7–10 days, cells were stained with 1% methylene blue and colonies
consisting of .50 cells were counted by microscopy. Surviving colonies were normalized for plating efficiency. Shown are average survival fractions
and SEM.
doi:10.1371/journal.pone.0069688.g002
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Figure 3. A. PLA-695 reduces proliferation in endothelial and lung cancer cells after irradiation. Equal numbers of bEND3, HUVEC, LLC
and A549 cells were plated in 96 well plates and treated with 300 nM PLA-695 for 45 min prior to treatment with 3 Gy. Cell proliferation was
determined using a colorimetric cell proliferation assay at 24, 48, 72 and 96 h post treatment. Shown is the absorbance at 490 nm. B. PLA-695
enhances cell death in irradiated lung cancer cells. LLC and A549 cells were treated with 300 nM PLA-695 or DMSO for 45 min prior to
treatment with 3 Gy. Cells were stained with Annexin V-APC and propidium iodide and analyzed by flow cytometry at 24, 48, 72 or 96 h after
irradiation. Shown are the line graphs indicating fold increase of cell death over control for each treatment with SEM from three experiments.
doi:10.1371/journal.pone.0069688.g003
Cytosolic PhospholipaseA2 Inhibition with PLA-695
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PLA-695 Reduces Endothelial Cell Migration after
Radiation
We performed gash closure assays with HUVEC and bEND3
cells to determine the effect of PLA-695 (Fig. 5). In this assay, a
wound was created in the cell culture(Baseline) and cells were
treated with vehicle (DMSO), vehicle and 3 Gy (DMSO+IR),
PLA-695 (300 nM), or a combination of PLA-695 and 3 Gy (PLA-
695+IR). Cell migration was calculated by counting the number of
cells moving into the wound (Fig. 5). We found that 24 hours after
treatment, the gash was nearly completely covered in HUVEC
and bEND3 cultures treated with DMSO. Irradiation alone led to
a reduction in migration in HUVEC (82%) and bEND3 (77%)
cells. Similar reduction was observed in cells treated with PLA-695
alone in both HUVEC (74%) and bEND3 (62%). The combina-
tion of PLA-695 and IR led to a significant reduction in the
migration of HUVEC (61%; P=0.003) and bEND3 (48%;
P= 0.012) cells when compared to IR alone (Fig. 5).
PLA-695 Reduces Tumor Cell Invasion after Radiation
cPLA2 has been implicated in cell migration, tubule
formation [26] and invasion [30]. We examined the effect of
PLA-695 on tumor cell invasion in LLC and A549 cell lines
using the transwell-invasion assays. In LLC, we observed a 24%
decrease in cell invasion when cells were irradiated with 4 Gy;
however, pre-treatment with 300 nM PLA-695 prior to IR
resulted in a 56% further reduction in cell invasion (P = 0.003;
Figure 4. PLA-695 enhances cell death in irradiated lung cancer cells. LLC and A549 cells were grown in chamber slides were treated with
300 nM PLA-695 or DMSO for 45 min prior to irradiation with 3 Gy. Cells were fixed 96 h later and stained with 49,6-diamidino-2-phenyllindole (DAPI).
Shown are the micrographs of DAPI stained cells, arrows indicate multinucleate cells and giant cells. Multinucleated and giant cells were counted in
five randomly selected fields. A bar graph depicting the average percent of multinucleate/giant cells for each treatment is shown.
doi:10.1371/journal.pone.0069688.g004
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Fig. 6). Treatment of LLC cells with PLA-695 alone showed a
63% reduction in invasion compared to control. Similarly in
A549 cells, radiation alone caused a 30% reduction in invasion,
while pre-treatment with 300 nM PLA-695 prior to IR reduced
invasion further by 37% (P ,0.001; Fig. 6).Treatment of A549
cells with PLA-695 alone produced a 58% reduction in invasion
compared to control.
Figure 5. PLA-695 reduces endothelial cell migration after radiation. HUVEC and bEND3 cells were plated on 60 mm plates and allowed to
grow to 80% confluency. The semi-confluent cell layer was scraped using a 200 ml sterile pipette tip to create a scratch/wound devoid of cells. The
remaining cells were treated with vehicle control or 300 nM PLA-695 for 45 min prior to IR with 3 Gy. Migration was assessed at 24 h after treatment.
The number of cells migrated in the scratch/wound were counted and normalized to surrounding cell density per HPF. Shown are representative
photomicrographs and bar graphs representing the mean percentages of migrating cells relative to corresponding controls with SEM from three
experiments.
doi:10.1371/journal.pone.0069688.g005
Cytosolic PhospholipaseA2 Inhibition with PLA-695
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PLA-695 Radiosensitizes Tumors in Animal Models of
NSCLC
To determine the efficacy of PLA-695 as a radiosesitizer in
NSCLC, we used heterotopic LLC and A549 tumor models grown
in C57 and nude mice, respectively. When the LLC and A549
tumors were palpable (range= 40–70 mm3), the mice were treated
for five consecutive days with DMSO (vehicle), irradiation (IR)
alone (10 Gy total, 5 fractions of 2 Gy), PLA-695 alone (7.5 mg/
kg/day, intraperitoneal), or a combination of PLA-695 and IR.
Subsequent tumor growth was monitored using a plethysmometer.
We analyzed tumor growth delay in these experiments in two
ways. First, the time for the tumor volume to reach a size of
0.25 cm3 was determined. Second, we analyzed the tumor
volumes on day 7 for LLC tumors and day 15 for A549 tumors
(Fig. 7). The LLC tumors grow much faster than A549 tumors.
Untreated tumors and IR treated tumors took 7 days to reach a
tumor volume of 0.25 cm3, while PLA-695 treated tumors took 7.5
days. Tumors treated with a combination of PLA-695 and IR took
9.5 days to reach a volume of 0.25 cm3. On day 7 the tumors
treated with a combination of PLA-695 and IR were smaller (0.13
cm3) compared to untreated (0.27 cm3; P= 0.019), IR alone
(0.24 cm3; P= 0.038) and PLA-695 alone (0.22 cm3; P = 0.100).
The enhancement of tumor growth delay by PLA-695 was more
pronounced in A549 tumor-bearing nude mice (Fig. 7). The
untreated A549 tumors reached the test volume (0.25 cm3) in 9
Figure 6. PLA-695 reduces tumor cell invasion after radiation. LLC and A549 cells were added to the 8 micron inserts and were treated with
300 nM PLA-695 or DMSO for 45 minutes prior to 3 Gy irradiation. Cells were allowed to invade/migrate from the top chamber through the coated
filter pores to the complete medium at the bottom of the inserts for 48 hour. Cells were then fixed, stained and cells that invaded through the
membrane was calculated by counting the number of cells per HPF. Shown are representative photomicrographs and a bar graph representing the
number of invasive cells with SEM; * p.0.05.
doi:10.1371/journal.pone.0069688.g006
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Figure 7. PLA-695 enhances tumor growth delay in heterotopic lung cancer tumors. LLC or A549 cells were implanted into the right
footpad of C57/BL6 mice. Tumors were irradiated with 2 Gy for 5 consecutive days for a total of 10 Gy. Mice were treated with 7.5 mg/Kg body
weight or vehicle control for 30 min prior to IR on days 1, 3, 5, 7 and 9. Shown are mean tumor volumes for LLC and A549 with SEM from each
treatment group of mice. Tumor growth delay for LLC and A549 tumors was calculated as the number of days for tumors to reach 0. 25 cm3(B).
Shown is a bar graph representing the mean tumor growth delay with SEM from each treatment group of 7 mice; * p,0.05. Tumor volumes were
analyzed on day 7 for LLC tumors and day 15 for A549 tumors. Shown is a bar graph representing the tumor growth on day 7 for LLC tumors and day
15 for A549 tumors with SEM from each treatment group of 6 mice; * p,0.05.
doi:10.1371/journal.pone.0069688.g007
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days, PLA-695 treated tumors (15 days) IR treated tumors (18
days) and PLA-695 in combination with IR treated tumors (32
days). On day 15, the A549 tumors treated with a combination of
PLA-695 and IR were significantly smaller (0.08 cm3) than
untreated tumors (0.407 cm3; P ,0.001), or IR (0.208 cm3; P
,0.001) or PLA-695 (0.258 cm3; P ,0.001) treated tumors.
Interestingly, two of the six tumors in the combination therapy
arm did not grow further throughout the duration of the study (37
days after first treatment) and one tumor regressed completely.
PLA-695 Damages Vessels in Tumors Treated with
Radiation
To determine the effects of cPLA2 inhibition with PLA-695 on
tumor vascularity, LLC tumors were treated similarly to those in
the tumor growth delay study. Microvessel density and cross
sectional area were determined by staining with an antibody
against VonWillebrand factor, an endothelial cell marker (Fig. 8A).
Analysis of sections of tumors subjected to various experimental
treatments indicated that there was no significant difference in the
number of vessels per high power field (HPF) in the various
experimental groups (Fig. 8 B). Tumors treated with DMSO
alone, PLA-695 alone and DMSO with IR had normal appearing
microvasculature, while tumors treated with a combination of
PLA-695 and IR had collapsed microvasculature (Fig. 8C).
Quantitation of the vascular cross-sectional area per HPF in the
treatments showed that there was a significant reduction in area
with combination therapy of PLA-695 and IR (Fig. 8 C, p,0.05),
while treatment with either radiation or drug alone showed no
statistically significant reductions in vascular area.
Combination Treatment of PLA-695 with Irradiation
Decreases Vascularity
We used a dorsal air sac model to study the effects of PLA-695
on tumor angiogenesis in- vivo. A chamber containing LLC cells
was inserted in the dorsal skin fold and treated with DMSO
(vehicle), IR alone (3 Gy), PLA-695 alone (7.5 mg/kg/day,
intraperitoneal), or combination of PLA-695 and IR. Mice treated
with IR showed increased microvasculature formation compared
to the controls. However, mice treated with PLA-695 alone or in
combination with IR showed destruction of microvasculature
(Fig. 9). PLA-695 treated LLC tumors showed a significant
decrease in microvasculature within the window model as
compared to untreated control or radiation alone (p,0.05).
Discussion
Previous studies have shown that cPLA2 is associated with
tumor progression and radioresistance of the tumor vasculature
[16,17,26]. cPLA2 is highly expressed in NSCLC [31,32].
Through the Washington University-Pfizer alliance, we obtained
inhibitors of cPLA2 with properties that are suitable for clinical
trials. PLA-695 is a potent and selective cPLA2 inhibitor that is
orally bio-available and has been the subject of Phase I and II
clinical trials aimed to determine its analgesic effect in sufferers of
chronic osteoarthritis (clinical trials.gov). Data from the clinical
trials showed that PLA-695 was effective analgesic when compared
to naproxen. Here we show that PLA-695 inhibited radiation-
induced signal transduction. Specifically, treatment with PLA-695
led to a dose-dependent attenuation of radiation-induced ERK
phosphorylation in HUVEC cells (Fig. 1). The Akt phosphoryla-
tion that occurs minutes following exposure to IR was also reduced
to baseline levels in these cells. Similar phosphorylation of ERK
and Akt was also seen in 3B11 cells. Clonogenic assays indicated
that inhibition of cPLA2 with PLA-695 did not sensitize LLC or
A549 cells to radiation (Fig. 2A). However, when the cancer cells
(LLC and A549) were grown in co-cultures with endothelial cells
(bEND3 and HUVEC) to simulate to tumor microenvironment,
and then treated with PLA-695, the cancer cells were radiosen-
sitized (Fig. 2B). These results indicated that the endothelium in
the tumor microenvironment may play an important role in the
response of the tumor to irradiation.
Treatment of endothelial and lung cancer cells with PLA-695
reduced proliferation at all the time points tested. On the other
hand, the combination of PLA-695 with IR led to further
reduction in proliferation at 48 h, 72 and 96 h (Fig. 3A).
Treatment with the combination of PLA-695 and IR in LLC
and A549 cells led to a treatment-time dependent increase of cell
death, as monitored by annexin V and PI (Fig. 3B). We have
shown earlier that cell death in endothelial cells after treatment
with the cPLA2 inhibitor AACOCF3 was associated with mitotic
catastrophe [17]. PLA-695 induced cell death increased at 96
hours post irradiation is similar to what we had reported earlier;
thus, the cell death induced by a combined treatment of PLA-695
and IR is likely to be due to mitotic catastrophe (Fig. 4).
Consideration of the data from the clonogenic, proliferation and
cell death studies leads to the conclusion that the treatments with a
combination of PLA-695 and IR led to increased cell death
contributing to reduced proliferation. Although PLA-695 is able to
reduce proliferation of both endothelial cells and tumor cells,
radiosensitization of tumor cells, LLC &A549, was detected only
when they were grown in co-culture and not as independent
cultures. Hence PLA-695 was effective as a radiosensitizer in the
tumor microenvironment. Invasion and migration are crucial for
tumorigenesis and proliferation of tumor cells. We found that
inhibition of cPLA2 by PLA-695 prior to IR significantly
attenuated invasion of LLC and A549 cells (Fig. 6). Combination
of PLA-695 and IR also reduced migration in HUVEC and
bEND3 cells (Fig. 5). Our findings in the heterotopic NSCLC
mouse tumor models add to the results of, previous studies, which
showed decreased tumorigenesis in mice genetically deficient in
cPLA2 or those treated with chemical inhibitors of the enzyme
[16,26]. Tumors grown in cPLA22/2 mice are smaller than
those grown in wild type mice [26]. In addition, tumor models
treated with a lipid-mimetic inhibitor of PLA2 exhibited a
significant tumor growth and decreased vascularity and perfusion
[16]. In the current study we found that PLA-695 exhibits a
similar effect in animal models of NSCLC. We have shown that
combination therapy with IR results in a statistically significant
tumor growth delay in both LLC and A549 lung tumor models
(Fig. 7). Most significantly, A549 tumors failed to grow in 50% of
the mice treated with PLA-695 and IR. The mechanism of action
of PLA-695 also concurs with previous studies, as combination
treated LLC tumors possessed significantly less vascular cross-
sectional area and significantly suppressed the formation of
microvessels and vascular network (Fig. 8). Results from the
tumor vascular window model (Fig. 9) also indicated that PLA-695
is anti-angiogenic when administered alone or in combination with
IR. Therefore, we have shown that cPLA2 plays an important role
in tumor blood vessel formation. Thus cPLA2 is an attractive
novel target for lung cancer treatment.
The radioresistance of tumor vasculature to conventionally
fractionated radiotherapy in difficult to treat cancers is well
documented [33]. While anti-angiogenic therapy is most certainly
not a new idea, with multiple agents having been developed in an
effort to inhibit tumor growth, these agents are rarely combined
with radiation and, by themselves, usually result only in transitory
clinical improvements that are subsequently followed by increased
drug resistance [34,35,36]. Thus, the development of novel and
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effective drugs that can radiosensitize the tumor vasculature
without serious side effects should improve the efficacy of tumor
control by radiation. In this study, we identified and characterized
PLA-695 as a selective and potent cPLA2 inhibitor capable of
radiosensitizing vascular endothelial cells and animal models of
lung cancer. Given PLA-695’s favorable pharmacological proper-
ties, combined with the results from this study, clinical testing of
this agent in NSCLC is warranted.
Figure 8. PLA-695 damages vessels in tumors treated with radiation. C57/BL6 mice with LLC tumors received i.p. injections of vehicle or
7.5 mg/kg PLA-695 30 min prior to IR with 2 Gy. Treatment was repeated for 5 consecutive days. Twenty-four hours after the final treatment, tumors
were harvested, fixed in 10% formalin, sectioned into 5-mm sections and stained with anti-vWF antibody. Shown are representative micrographs of
vWF-stained vessels and bar graphs of the average number of stained vessels per HPF and percent vascular area per HPF with SE from group of 5
mice; *, P,0.05.
doi:10.1371/journal.pone.0069688.g008
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